Abstract
Ischemic stroke represents a significant societal burden across the globe. Rare high penetrant monogenic variants and less pathogenic common single nucleotide polymorphisms (SNPs) have been described as being associated with risk of diseases. Genetic studies in Saudi Arabian patients offer a greater opportunity to detect rare high penetrant mutations enriched in these consanguineous populations. We performed whole exome sequencing on 387 ischemic stroke subjects from Saudi Arabian hospital networks with up to 20,230 controls from the Saudi Human Genome Project and performed gene burden analyses of variants in 177 a priori loci derived from knowledge-driven curation of monogenic and genome-wide association studies of stroke. Using gene-burden analyses, we observed significant associations in numerous loci under autosomal dominant and/or recessive modelling. Stroke subjects with modified Rankin Scale (mRSs) above 3 were found to carry greater cumulative polygenic risk score (PRS) from rare variants in stroke genes (standardized PRS mean > 0) compared to the population average (standardized PRS mean = 0). However, patients with mRS of 3 or lower had lower cumulative genetic risk from rare variants in stroke genes (OR (95%CI) = 1.79 (1.29–2.49), p = 0.0005), with the means of standardized PRS at or lower than 0. In conclusion, gene burden testing in Saudi stroke populations reveals a number of statistically significant signals under different disease inheritance models. However, interestingly, stroke subjects with mRS of 3 or lower had lower cumulative genetic risk from rare variants in stroke genes and therefore, determining the potential mRS cutoffs to use for clinical significance may allow risk stratification of this population.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Stroke is a major cause of morbidity and is the second leading cause of death worldwide. Over 13 million people have a stroke each year and around 5.5 million people will die as a result (Virani et al. 2021). Incidence, type of stroke and mortality rates vary markedly between countries and ancestral groups. Ischemic strokes are the most common type of stroke, and typically involve a disruption of blood flow to the brain parenchyma which causes brain cell death from a lack of oxygen. It may result from a number of processes including small vessel occlusions (SVOs) and large-artery atherosclerosis (Adams et al. 1993). More young people are affected with ischemic stroke in low- and middle-income countries than higher income countries (Lehman and Fullerton 2013; Lehman et al. 2018). Initial twin and family studies, primarily using linkage analysis, contributed to the initial knowledge of heritability studies in stroke (Flossmann et al. 2004). While such approaches found causal variants in various genes for monogenic stroke disorders, they had limited value in finding common variants impacting polygenic risk (Ekkert et al. 2021; Li et al. 2021). Genome-Wide Association Studies (GWAS) utilizing genome-wide genotyping arrays and/or whole exome sequencing (WES) have been successful in elucidating rare and common variants in various stroke subtypes (Li et al. 2021; Dichgans et al. 2021; Kumar et al. 2021).
Polygenic risk scores (PRS) utilizing cumulative, weighted risk scores for multiple genetic variants, with specific diseases/phenotypes, typically integrate known clinical risk covariates. They have been used with varying success in common diseases with multifactorial disease risk, including those with common and rare genetic underpinnings. Malik and colleagues combined stroke PRS data with Framingham risk scores and observed a significant association with ischemic stroke risk, although the prognostic value of the PRS was not substantially different from that of conventional clinical risk factors (Malik et al. 2014). However, more recent studies have shown utility with the use of PRSs in stroke-related phenotypes (Hachiya et al. 2020).
Saudi Arabia has seen an unprecedented adverse rise in modifiable risk factors for vascular disease over the last 30–40 years including poor diet, smoking and sedentary lifestyle, resulting in increases in dyslipidemia, type 2 diabetes, and hypertension which further exacerbate stroke and other vascular disease progression (Alhazzani et al. 2021). There are wide incidence differences across reported Saudi stroke studies ranging from ~ 16 to 58 cases per 100,000 person years (Alhazzani et al. 2018; Al Rajeh & Awada 2002). Such differences may be due to an interplay of study ascertainment biases as well as from significant primary and secondary health care delivery differences between private and public payer systems in Saudi Arabia, leading to a higher likelihood of undiagnosed diseases (Alqahtani et al. 2020). Recent studies indicate that the incidence of stroke is increasing rapidly with ischemic stroke being the dominant subtype affecting the Saudi populations (Alhazzani et al. 2018; Alqahtani et al. 2020; Al Rajeh & Awada 2002; Alqahtani et al. 2020).
Performing genetic studies in Saudi Arabian populations offers a unique opportunity for the discovery of novel genetic variants impacting disease risk due to a high rate of consanguinity amongst tribal pedigrees that make up the majority of the national population (Kari et al. 2014; Alkuraya 2012). We performed whole exome sequencing on 387 Saudi subjects with clinically diagnosed ischemic stroke. We focused on the analyses of exonic sequence data from a panel of 177 gene regions derived from highly curated stroke studies and utilized approximately 20,230 controls from the Saudi Human Genome Project. We then assessed the association of rare variants, primarily with ischemic stroke, and also evaluated PRSs within our study population.
Methods
Study participants’ samples and data
During 2019–2020, samples and data from 387 subjects (inpatients and outpatients) who had been diagnosed with ischemic stroke and attending the following Neurology Clinics were collected for inclusion in this study: King Fahd Hospital of the University (KFHU), Al Khobar; King Fahd Hospital, Al Hafof; and Al Wajh Hospital, Dammam. Participants ranged in age from 19 to 81. The phenotype data of all subjects were reviewed by a neurology consultant to ascertain and verify the diagnoses and the phenotype uniformity among sites as well as eligibility according to the study criteria. Table 1 outlines the demographic and clinical characteristics of the 387 ischemic stroke subjects included in this study. The subtypes of ischemic stroke were determined according to the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification (Adams et al. 1993). The functional outcome of stroke patients was determined using modified Rankin Scale (mRS) at admission and at one-month post stroke follow-up.
DNA extraction and sequencing
Peripheral blood samples were collected into EDTA tubes and stored in − 20 °C freezers at the research laboratories at the College of Medicine, Imam Abdulrahman bin Faisal University. Genomic DNA extraction from all samples was performed using Gentra Puregene Blood kits (Qiagen, USA) according to the manufacturer’s protocol. Whole exome sequencing libraries were generated using the SureSelect Human All Exon Kit v5 (Agilent, CA, USA) and sequenced on a HiSeq instrument (Illumina, CA, USA) using a standard paired-end sequencing protocol for SureSelectXT Library Prep and Target Enrichment System Version B.2 (Illumina, CA, USA).
Read alignment, variant calling, and QC
Reads in the FASTQ files were aligned to the standard human genome reference (GRCh37) using Illumina’s Dynamic Read Analysis dor GENNomics (DRAGEN) Genomic Pipeline. Resultant BAM files were position-sorted and duplicate reads marked. Single-sample genomic variant call files (gVCF) were generated by the DRAGEN Germline Pipeline, and joint calling of all samples in the study cohort was performed by DRAGEN Joint Genotyping (Illumina, CA, USA).
Principal components analysis (PCA) and Kinship
The KING algorithm was used for relatedness inference based on the genotype of exome SNPs (minor allele frequency [MAF] > 0.01). Estimated kinship coefficient and number of SNPs with zero shared alleles (identity by state [IBS]0) between a pair of individuals were plotted. Parent-offspring, sibling pairs, and unrelated pairs were visualized on the scatterplot to distinguish any separate clusters. Ancestry and Kinship Toolkit (AKT) was used to calculate PCAs and plot the results using 1000 genome project data. The study participant samples demonstrated a genetically matched background consistent with typical Saudi populations including African admixture, which is known to be evident in Saudi tribes primarily from East Africa (Fernandes et al. 2019).
Variant annotation, filtering and prioritization
Variants were annotated with a program for annotating and predicting the effects of single nucleotide polymorphisms (SnpEff,v5.0) to predict the effects of the variants. Rare variants were defined as minor allele frequency (MAF) < 1% in The Genome Aggregation Database (gnomAD) (v2.1.1). Intronic, synonymous, 3′ and 5′ UTR, upstream and downstream variants were identified and excluded from the analysis. The remaining rare variants were considered to be potentially deleterious variants. Genetic variants classified in ClinVar as “Likely pathogenic” or “Pathogenic,” and in Human Gene Mutation Database (HGMD) as disease-causing mutations (DM) for stroke were collected and curated together with research literature to serve as the knowledgebase for variant prioritization and classification (Stenson et al. 2003).
Use of a comprehensive stroke gene panel
Numerous reports have identified genes associated with stroke by using data from monogenic and genome-wide association studies (GWAS). We used a comprehensive collation of genes with associations for monogenic causes of stroke which has been used in many clinical and research studies (Ilinca et al. 2019). Malek et al. in a large multi-ancestry GWAS of up to 67,162 stroke cases and 454,450 controls discovered 22 new stroke risk loci and validated 10 known stroke loci, bringing the total to 32 loci which are encompassed in the panel (Malik et al. 2018).
Gene burden testing
The open-source software package Test Rare vAriants with Public Data (TRAPD) was used to perform a gene-based burden testing against public control databases. The software allows for adaptable filtering on various quality and frequency fields to ensure a well-controlled burden test. Gene burden test on our ischemic stroke WES cohort datasets was performed against whole exome or whole genome sequencing data available from approximately 20,230 individuals from the Saudi Human Genome Project (https://shgp.kacst.edu.sa).
Polygenetic risk score generation
Rare, impactful variants (listed in Supplementary Table S1) identified in stroke genes were included to calculate polygenetic risk scores (PRS) for stroke for each individual study subject to represent the cumulative risk of carrying one or more of these rare variants. (Malik et al. 2018). PRSice-2 software was employed to calculate PRS by setting an equal effect size (beta = 1) for each variant (Choi and O’Reilly 2019). The resulting PRS was standardized for association tests with clinical variables such as age of diagnosis, mRS, and classifications of stroke. It is acknowledged that there may be an under- or over-estimation of the effect size of these rare variants. However, when there is an actual effect, the association, albeit with less accurate estimates, could be detected. The validity of this approach was evident in the initial effort to estimate the combined effect of multiple genetic variants before a more sophisticated statistical approach was developed (Zheng et al. 2008). In addition, as the rare variant PRS was calculated using PRSice-2, it was restricted to the specific set of rare variants that were identified without consideration of other common variants based on LD patterns.
Results
Principal component analysis
The common variants of the whole exome sequencing data from the stroke study participants show expected clustering when compared to the world’s major populations using a standard principal component analysis pipeline (Fig. 1). This population stratification data was used to mitigate false attributions in the association analyses components.
Gene burden testing
We were able to utilize exonic data from 177 genes from the initial set of 214 stroke loci panel (48) after removal of mitochondrial genes; non-exonic regions such as 9p.21 and non-coding RNAs, and genes that had poor quality control and quality assurance filtering data in the Saudi Genome Project control dataset including ATP7A, FLNA, GLA, GPR143, PGAM4, and F9. Focusing on the a priori 177 loci derived from the stroke panel, we identified rare putative impactful variants within the cohort (Supplementary Table S1). The equivalent analysis was performed using the TRAPD burden testing pipeline and we observed that our cohort of 387 ischemic stroke subjects was significantly enriched for impactful alleles in several loci on the a priori stroke panel, compared to the control populations of approximately 20,230 Saudi population-based controls derived from the Saudi Genome Project.
The top 20 most significant signals for gene burden analyses under a dominant model (p < 1 × 10–5) and 14 signals with p < 0.05) under a recessive model are shown on Table 2 with FDR correction and a full list of association signals under both dominant and recessive models are shown for all 177 genes (Supplementary Table S2). Table 2 (top) shows the top 20 genes with p < 1 × 10−5 under a dominant model (F13A1, NF1, ACAD9, NOTCH3, MYLK, SH3PXD2A, TSC2, ADAMTS13, COL4A2, APP, FOXC1, COL1A1, TGFBR2, PDE4D, MYH7, DPM1, PGM1, FCGR2C, ZFHX3, PDE3A). Table 2 (top) shows the 14 most significant signals at p < 0.05 under a recessive model (PDE4D, KCNQ1, TREX1, CYP11B1, F5, HTRA1, CACNA1A, ZCCHC14, NBEAL2, FGA, PCNT, DPM1, LOC100505841, and SH3PXD2A). Three genes, SH3PXD2A, PDE4D, and DPM1, were significant under both the dominant and recessive models. Twenty-eight of the genic 32 GWAS loci contained among the 177 genes on the stroke panel were available for analysis and 12 showed gene burden associations at p < 0.05 under either dominant or recessive models (ZCCHC14, FGA, LOC100505841, SH3PXD2A, PRPF8, PDE3A, ZFHX3, SH2B3, TM4SF4, HDAC9–TWIST1, SMARCA4, and FOXF2).
Associations of polygenic risk with clinical variables
The overall distribution of polygenic risk score (PRS) representing the overall genetic burden from rare, impactful variants in stroke genes among all 387 ischemic stroke study participants subjected to whole exome sequencing deviated from normality and was right-skewed (Fig. 2) with median [IQR] of 8.61 [6.59,10.53], minimum of 1.53, and maximum of 18.75. PRS was not associated with age of diagnosis, ischemia diagnosis, and classification of stroke such as large artery atherosclerosis, cardio aortic embolism, and small artery occlusion (Table 3). However, a significant association of PRS and mRS, which measures the degree of disability post-stroke, was identified (regression coefficient (95%CI) = 0.15 (0.03–0.27), p = 0.02). PRS was found to increase the risk of developing greater disability post-stroke event (mRS > 3), when compared to patients with lower mRS (mRS ≤ 3) (OR (95%CI) = 1.79 (1.29–2.49), p = 0.0005) (Table 3).
Stroke subjects with mRSs above 3 were found to carry greater cumulative genetic risk from rare variants in stroke genes (standardized PRS mean > 0) compared to the population average (standardized PRS mean = 0). However, patients with mRS of 3 or lower had lower cumulative genetic risk from rare variants in stroke genes, with the means of standardized PRS at or lower than 0 (Fig. 3).
Discussion
In this study, WES was performed on 387 individuals diagnosed with ischemic stroke. We initially focused on known, or putative, pathogenic exonic variants evident in 177 genes prioritized from a comprehensive panel of loci associated with monogenic causes of stroke as well as recent GWAS statistically significant signals (Ilinca et al. 2019). This panel has been used in exome sequencing interpretation of individuals from multi-incident stroke families to generate and assess putative pathogenic variants amongst the probands and wider family members (Ilinca et al. 2020). It has also been utilized in cerebral small vessel disease (CSVD) which revealed putative pathogenic variants in multiple loci (Monkare et al. 2022). Using the TRAPD gene burden testing pipeline, filtered on our list of 177 genes, we found significant enrichment for pathogenic or likely pathogenic stroke variants in numerous genes in our cohort using datasets from the Saudi Genome Project as controls.
A number of the top signals in our study are outlined below. The coagulation factor XIII A chain (F13A1) gene encodes the coagulation factor that is the last component activated in the blood coagulation cascade. Factor XIII deficiency is typically classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in defective wound healing and a tendency for lifelong bleeding. A review of common variants association analyses of F13A1 with stroke phenotypes has shown mixed findings. However, a large Women’s Health Initiative (WHI) study of 2,045 of post-menopausal women, significant risk was observed for both ischemic stroke and for combined ischemic and hemorrhagic between two common F13A1 variants and with hormone replacement therapy (Huang et al. 2012). A Dutch study also showed significant associations between common variants in F13A1 with ischemic stroke in young women with the effect more pronounced with oral contraception use (Pruissen et al. 2008).
Neurofibromin 1 (NF1) gene encodes a negative regulator of the Ras signal transduction pathway and a number of NF1 mutations have been linked to neurofibromatosis type 1 which is commonly associated with malignant tumors and cardiovascular or cerebrovascular complications (Napolitano et al. 2022). Neurofibromatosis type 1 also increases the risk of vasculopathies and arterial wall weakness and can lead to complications such as hemorrhagic stroke, ischemic stroke, and multi-domain cognitive impairment (Napolitano et al. 2022).
Acyl-CoA dehydrogenase family member 9 (ACAD9) encodes a member of the acyl-CoA dehydrogenase family, a family of proteins that are localized in the mitochondria and are involved in beta-oxidation of fatty acyl-CoA. Mutations in this gene cause acyl-CoA dehydrogenase family member type 9 deficiency which often results in intellectual disability and neurologic dysfunction. A homozygous variant in ACAD9 was identified in the proband of a Swedish family where family members reported stroke with intracerebral bleeding and progressive muscle and heart failure (Ilinca et al. 2020). A case report of a death of a teenager with ACAD9 deficiency with Reye-like episode and cerebellar stroke has also been reported (Huang et al. 2012).
Phosphodiesterase 4D (PDE4D) encodes up to 9 different isoforms whose functional proteins degrade the second messenger Cyclic adenosine monophosphate (cAMP), a key signal transduction molecule in multiple cell types, including vascular cells (Munshi & Kaul 2008). Numerous case–control studies have been performed to assess the association between PDE4D variants and ischemic stroke risk among different ancestral populations. In particular, the so-called “SNP83” (rs966221) association with has been robust in many of these studies (Munshi & Kaul 2008; Xu et al. 2010). PDE4D is associated with inflammation and reduced PDE4D is thought to increase the risk of atrial fibrillation, which in turn increases stroke risk (Jørgensen et al. 2015). Several studies have shown a robust association of PDE4D variants with ischemic stroke in young individuals (Yue et al. 2019).
Potassium voltage-gated channel subfamily Q member 1 (KCNQ1) encodes a voltage-gated potassium channel protein which is required for the repolarization phase of the cardiac action potential and forms multimers with KCNE1, KCNE3 and potassium channel proteins. Mutations in KCNQ1 are associated with familial atrial fibrillation and hereditary long QT syndrome 1 which can impact stroke risk (Jørgensen et al. 2015; Lavy et al. 1974). An increased genetic burden of rare deleterious KCNQ1 variants in Polish subjects with large‑vessel ischemic stroke were identified using second-generation sequencing (Janicki et al. 2019).
Three prime repair exonuclease 1 (TREX1) encodes a nuclear protein with 3′ exonuclease activity and play a role in DNA repair and serve as a proofreading function for DNA polymerase. Mutations in this gene result in diseases of the immune system including Aicardi-Goutieres syndrome and other autoimmune-type diseases which can put subjects at a higher risk of ischemic stroke. Uemura 2023 investigating the prevalence of Mendelian stroke genes mutations in monogenic cerebral small vessel stroke patients aged 55 years or younger from a Japanese stroke registry identified a TREX1 pathogenic genetic variants in one stroke subject (Uemura et al. 2023). A large Mendelian Stroke Consortium also identified pathogenic clinical variants in TREX1 (Grami et al. 2020).
The distribution of the polygenic risk score analyses showed that the stroke subjects in this Saudi cohort each, on average, carry over 8 rare, impactful variants. PRS analyses performed on a weighted cumulative risk from rare, impactful variants among ischemic stroke participants with high Modified Rankin Scale (mRS), i.e., 4, 5, 6 versus mRS 0, 1, 2, 3 showed a significant association (OR (95%CI) = 1.79 (1.29–2.49), p = 0.0005). Determining the potential mRS cutoffs to use for clinical significance within a highly consanguineous population like that in Saudi Arabia may yield translational value, such as risk stratification, especially with the additional of common and rare variants to the PRS from ongoing stroke genome-wide studies.
In Saudi Arabia, undetected or untreated vascular disease is a significant health and financial burden,(Walli-Attaei et al. 2020a, b; Bindawas & Vennu 2016). There is a compelling need for implementation of primary and secondary stroke prevention strategies in Saudi Arabia due to an increasing incidence rate with the mortality rate projected to almost double by 2030 (Robert et al. 2018; Bindawas & Vennu 2016). In this study using gene-burden analyses in 387 Saudi Arabian ischemic stroke subjects and 20,230 controls from the Saudi Human Genome Project, we observed significant associations in dozens of loci under autosomal dominant and/or recessive modelling. Stroke subjects with Modified Rankin Scale (mRSs) above 3 were observed to have a greater cumulative PRS from rare variants in stroke genes when compared to the population average. Interestingly, stroke subjects with mRS of 3 or lower had lower cumulative genetic risk from rare variants in stroke genes (Alokley and Albakr 2022). Determining the potential mRS cutoffs to use for clinical significance may allow risk stratification of this population.
Data availability
The datasets generated during the current study are available in the European Variation Archive (EVA) repository (https://www.ebi.ac.uk/ebisearch/search?query=PRJEB59227&submit=Search&db=allebi&requestFrom=global-masthead), under the title Whole‐Exome Sequencing Analyses in a Saudi Ischemic Stroke Cohort Reveal Association Signals and shows Polygenic Risk Scores are related to Modified Rankin Scale Risk with accession number PRJEB59227. All requests for data can be sent to the corresponding author (AKA) and verified academic investigators will be granted full access.
References
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1):35–41. https://doi.org/10.1161/01.str.24.1.35
Al Rajeh S, Awada A (2002) Stroke in Saudi Arabia. Cerebrovasc Dis 13(1):3–8. https://doi.org/10.1159/000047738
Alhazzani AA, Mahfouz AA, Abolyazid AY, Awadalla NJ (2021) Risk factors of the first-time stroke in the Southwest of Saudi Arabia: a case-control study. Brain Sci 11(2). https://doi.org/10.3390/brainsci11020222
Alhazzani AA, Mahfouz AA, Abolyazid AY, Awadalla NJ, Aftab R, Faraheen A, Khalil SN (2018) Study of stroke incidence in the Aseer Region, Southwestern Saudi Arabia. Int J Environ Res Public Health 15(2). https://doi.org/10.3390/ijerph15020215
Alkuraya, FS (2012) Discovery of rare homozygous mutations from studies of consanguineous pedigrees. Curr Protoc Hum Genet, Chapter 6, pp. Unit6.12. https://doi.org/10.1002/0471142905.hg0612s75
Alokley AA, Albakr A (2022) Intracerebral hemorrhages related to clinical conditions and associated outcomes among Saudi and Non-Saudi Patients in a University Hospital: a retrospective study. Prim Care Companion CNS Disord 24(5). https://doi.org/10.4088/PCC.21m03192
Alqahtani BA, Alenazi AM, Hoover JC, Alshehri MM, Alghamdi MS, Osailan AM, Khunti K (2020) Incidence of stroke among Saudi population: a systematic review and meta-analysis. Neurol Sci 41(11):3099–3104. https://doi.org/10.1007/s10072-020-04520-4
Bindawas SM, Vennu VS (2016) Stroke rehabilitation A call to action in Saudi Arabia. Neurosciences (Riyadh) 21(4):297–305. https://doi.org/10.17712/nsj.2016.4.20160075
Choi SW, O’Reilly PF (2019) PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience 8(7). https://doi.org/10.1093/gigascience/giz082
Dichgans M, Beaufort N, Debette S, Anderson CD (2021) Stroke genetics: turning discoveries into clinical applications. Stroke 52(9):2974–2982. https://doi.org/10.1161/STROKEAHA.121.032616
Ekkert A, Šliachtenko A, Grigaitė J, Burnytė B, Utkus A, Jatužis D (2021) Ischemic stroke genetics: what is new and how to apply it in clinical practice?. Genes (Basel) 13(1). https://doi.org/10.3390/genes13010048
Fernandes V, Brucato N, Ferreira JC, Pedro N, Cavadas B, Ricaut FX, Alshamali F, Pereira L (2019) Genome-wide characterization of arabian peninsula populations: shedding light on the history of a fundamental bridge between continents. Mol Biol Evol 36(3):575–586. https://doi.org/10.1093/molbev/msz005
Flossmann E, Schulz UG, Rothwell PM (2004) Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 35(1):212–227. https://doi.org/10.1161/01.STR.0000107187.84390.AA
Grami N, Chong M, Lali R, Mohammadi-Shemirani P, Henshall DE, Rannikmäe K, Paré G (2020) Global assessment of Mendelian stroke genetic prevalence in 101 635 individuals from 7 ethnic groups. Stroke 51(4):1290–1293. https://doi.org/10.1161/STROKEAHA.119.028840
Hachiya T, Hata J, Hirakawa Y, Yoshida D, Furuta Y, Kitazono T, Shimizu A, Ninomiya T (2020) Genome-wide polygenic score and the risk of ischemic stroke in a prospective cohort: the Hisayama study. Stroke 51(3):759–765. https://doi.org/10.1161/STROKEAHA.119.027520
Huang Y, Ballinger DG, Stokowski R, Beilharz E, Robinson JG, Liu S, Robinson RD, Henderson VW, Rossouw JE, Prentice RL (2012) Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med 4(7):57. https://doi.org/10.1186/gm358
Ilinca A, Samuelsson S, Piccinelli P, Soller M, Kristoffersson U, Lindgren AG (2019) A stroke gene panel for whole-exome sequencing. Eur J Hum Genet 27(2):317–324. https://doi.org/10.1038/s41431-018-0274-4
Ilinca A, Martinez-Majander N, Samuelsson S, Piccinelli P, Truvé K, Cole J, Kittner S, Soller M, Kristoffersson U, Tatlisumak T, Puschmann A, Putaala J, Lindgren A (2020) Whole-exome sequencing in 22 Young ischemic stroke patients with familial clustering of stroke. Stroke 51(4):1056–1063. https://doi.org/10.1161/STROKEAHA.119.027474
Janicki PK, Eyileten C, Ruiz-Velasco V, Pordzik J, Czlonkowska A, Kurkowska-Jastrzebska I, Sugino S, Imamura Kawasawa Y, Mirowska-Guzel D, Postula M (2019) Increased burden of rare deleterious variants of the KCNQ1 gene in patients with large-vessel ischemic stroke. Mol Med Rep 19(4):3263–3272. https://doi.org/10.3892/mmr.2019.9987
Jørgensen C, Yasmeen S, Iversen HK, Kruuse C (2015) Phosphodiesterase4D (PDE4D)–a risk factor for atrial fibrillation and stroke? J Neurol Sci 359(1–2):266–274. https://doi.org/10.1016/j.jns.2015.11.010
Kari JA, Bockenhauer D, Stanescu H, Gari M, Kleta R, Singh AK (2014) Consanguinity in Saudi Arabia: a unique opportunity for pediatric kidney research. Am J Kidney Dis 63(2):304–310. https://doi.org/10.1053/j.ajkd.2013.08.033
Kumar A, Chauhan G, Sharma S, Dabla S, Sylaja PN, Chaudhary N, Gupta S, Agrawal CS, Anand KS, Srivastava AK, Vibha D, Sagar R, Raj R, Maheshwari A, Vivekanandhan S, Kaul B, Raghavan S, Gorthi SP, Mohania D, Kaushik S, Yadav RK, Hazarika A, Sharma P, Prasad K (2021) Association of SUMOylation pathway genes with stroke in a genome-wide association study in India. Neurology 97(4):e345–e356. https://doi.org/10.1212/WNL.0000000000012258
Lavy S, Yaar I, Melamed E, Stern S (1974) The effect of acute stroke on cardiac functions as observed in an intensive stroke care unit. Stroke 5(6):775–780. https://doi.org/10.1161/01.str.5.6.775
Lehman LL, Fullerton HJ (2013) Changing ethnic disparity in ischemic stroke mortality in US children after the STOP trial. JAMA Pediatr 167(8):754–758. https://doi.org/10.1001/jamapediatrics.2013.89
Lehman LL, Khoury JC, Taylor JM, Yeramaneni S, Sucharew H, Alwell K, Moomaw CJ, Peariso K, Flaherty M, Khatri P, Broderick JP, Kissela BM, Kleindorfer DO (2018) Pediatric stroke rates over 17 years: report from a population-based study. J Child Neurol 33(7):463–467. https://doi.org/10.1177/0883073818767039
Li J, Chaudhary DP, Khan A, Griessenauer C, Carey DJ, Zand R, Abedi V (2021) Polygenic risk scores augment stroke subtyping. Neurol Genet 7(2):e560. https://doi.org/10.1212/NXG.0000000000000560
Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A et al (2018) Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 50(4):524–537. https://doi.org/10.1038/s41588-018-0058-3
Malik R, Bevan S, Nalls MA, Holliday EG, Devan WJ, Cheng YC, Ibrahim-Verbaas CA, Verhaaren BF, Bis JC, Joon AY, de Stefano AL, Fornage M, Psaty BM, Ikram MA, Launer LJ, van Duijn CM, Sharma P, Mitchell BD, Rosand J, Meschia JF, Levi C, Rothwell PM, Sudlow C, Markus HS, Seshadri S, Dichgans M, Wellcome Trust Case Control Consortium 2 (2014) Multilocus genetic risk score associates with ischemic stroke in case-control and prospective cohort studies. Stroke 45(2):394–402
Monkare S, Kuuluvainen L, Schleutker J, Bras J, Roine S, Poyhonen M et al (2022) Genetic analysis reveals novel variants for vascular cognitive impairment. Acta Neurol Scand 146(1):42–50. https://doi.org/10.1111/ane.13613
Munshi A, Kaul S (2008) Stroke genetics–focus on PDE4D gene. Int J Stroke 3(3):188–192. https://doi.org/10.1111/j.1747-4949.2008.00199.x
Napolitano F, Dell’Aquila M, Terracciano C, Franzese G, Gentile MT, Piluso G, Santoro C, Colavito D, Patanè A, De Blasiis P, Sampaolo S, Paladino S, Melone MAB (2022) Genotype-phenotype correlations in neurofibromatosis type 1: identification of novel and recurrent. Genes (Basel) 13(7). https://doi.org/10.3390/genes13071130
Pruissen DM, Slooter AJ, Rosendaal FR, van der Graaf Y, Algra A (2008) Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 111(3):1282–1286. https://doi.org/10.1182/blood-2007-08-110254
Robert AA, Al-Dawish A, Mujammami M, Dawish MAA (2018) Type 1 diabetes mellitus in Saudi Arabia: a soaring epidemic. Int J Pediatr 2018:9408370. https://doi.org/10.1155/2018/9408370
Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN (2003) Human gene mutation database (HGMD): 2003 update. Hum Mutat 21(6):577–581. https://doi.org/10.1002/humu.10212
Uemura M, Hatano Y, Nozaki H, Ando S, Kondo H, Hanazono A, Iwanaga A, Murota H, Osakada Y, Osaki M, Kanazawa M, Kanai M, Shibata Y, Saika R, Miyatake T, Aizawa H, Ikeuchi T, Tomimoto H, Mizuta I, Mizuno T, Ishihara T, Onodera O (2023) High frequency of. J Neurol Neurosurg Psychiatry 94(1):74–81. https://doi.org/10.1136/jnnp-2022-329917
Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW (2021) Heart Disease and Stroke Statistics-2021 update: a report from the american heart association. Circulation 143(8):e254–e743. https://doi.org/10.1161/CIR.0000000000000950
Walli-Attaei M, Joseph P, Rosengren A, Chow CK, Rangarajan S, Lear SA et al (2020a) Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 396(10244):97–109. https://doi.org/10.1016/S0140-6736(20)30543-2
Walli-Attaei M, Joseph P, Rosengren A, Chow CK, Rangarajan S, Lear SA, AlHabib KF, Davletov K, Dans A, Lanas F, Yeates K, Poirier P, Teo KK, Bahonar A, Camilo F, Chifamba J, Diaz R, Didkowska JA, Irazola V, Ismail R, Kaur M, Khatib R, Liu X, Mańczuk M, Miranda JJ, Oguz A, Perez-Mayorga M, Szuba A, Tsolekile LP, Prasad Varma R, Yusufali A, Yusuf R, Wei L, Anand SS, Yusuf S (2020b) Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 396(10244):97–109. https://doi.org/10.1016/S0140-6736(20)30543-2
Xu X, Li X, Li J, Ou R, Sheng W (2010) Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations. Neurogenetics 11(3):327–333. https://doi.org/10.1007/s10048-010-0235-8
Yue X, Lixia L, Yan H, Zhang P, Gui Y, Song J (2019) Association between PDE4D polymorphism and ischemic stroke in young population. Saudi J Biol Sci 26(5):1023–1026. https://doi.org/10.1016/j.sjbs.2019.04.007
Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Grönberg H (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358(9):910–919. https://doi.org/10.1056/NEJMoa075819
Acknowledgements
The authors would like to acknowledge the financial support provided by King Abdulaziz City for Science & Technology. We are also grateful to the nurses, technical staff, and students for their efforts, commitment, and dedication. We would like to thank the Saudi Human Genome Project (SHGP), King Abdulaziz City for Science and Technology.
Funding
This work is supported by King Abdulaziz City for Science and Technology, Riyad, Saudi Arabia, grant number 14-MED1918-46. This is a government agency which plays no role in the design, collection, analysis and interpretation of the data and writing of the manuscript.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, patient recruitment, and data collection were performed by Fahad A. Alkhamis, Majed M. Alabdali, Abdulla A Alsulaiman, Abdullah S. Alamri, Rudaynah Alali, Sadiq A. Alsalman, Aishah I Albakr, and Anas S. Alduhalan. Laboratory work, analysis, and interpretation of data were performed by Mohammed S. Akhtar, Cyril Cyrus, Divya Gandla, Khaldoun Al- Romaih, Mohamed Abouelhoda, Bao-Li Loza, Brendan Keating, and Amein K. Al-Ali and the manuscript was written by Brendan Keating and Amein K. Al-Ali. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
Ethical approval for the study was obtained from the Imam Abdulrahman bin Faisal University Institutional Review Board (IRB) committees (IRB# 20–1401349) and the study was conducted according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All subjects included in the study signed a written informed consent form in English, with a verified translation provided in Arabic. For those participants who were unable to sign due to the effects of the stroke, the next of kin was requested to sign the informed written consent.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Alkhamis, F.A., Alabdali, M.M., Alsulaiman, A.A. et al. Whole‐exome sequencing analyses in a Saudi Ischemic Stroke Cohort reveal association signals, and shows polygenic risk scores are related to Modified Rankin Scale Risk. Funct Integr Genomics 23, 102 (2023). https://doi.org/10.1007/s10142-023-01039-7
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01039-7